InterCure (NASDAQ:INCR) Trading Up 3% – Still a Buy?

InterCure Ltd. (NASDAQ:INCR) traded up 3% during mid-day trading on Wednesday . The stock traded as high as $0.7878 and last traded at $0.7734. 2,446 shares traded hands during trading, a decline of 91% from the average session volume of 25,973 shares. The stock had previously closed at $0.7509.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of InterCure in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, InterCure presently has a consensus rating of “Sell”.

InterCure Stock Performance

The firm has a fifty day simple moving average of $0.84 and a 200-day simple moving average of $1.16.

About InterCure

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.